Annual report
6523.TEDINET S100R2R0
Period2022-04-01 → 2023-03-31
Filed2023-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥356.4bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥340.5bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥306.1bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥272.6bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥186.5bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥20.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥8.2bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥179m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥22.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥5.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.6bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥8.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥16.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥5.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥15.5bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | −¥3.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥8.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥561.6bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥591.3bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥569.3bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥529.8bn | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥325.2bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥422.7bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥455.3bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥138.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥136.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥107.6bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥138.0bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥135.4bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥107.0bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥70.3bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥65.3bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥95.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥60.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥45.4bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥50.1bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥21.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥51.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥47.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥36.9bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥33.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥17.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥12.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥16.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥135.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥7.4bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥20.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥95.6bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥19.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥149.07 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥46.61 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥135.84 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-25.84 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-70.78 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥143.93 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥45.22 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥130.45 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,101.33 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,092.33 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥921.04 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥619.38 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥579.44 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 24.6% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 22.9% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 13.3% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 20.1% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | -2.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -7.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 19.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.8% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 26.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 9,403 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 9,374 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 9,753 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 9,615 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,368 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥32.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥39.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.8bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.8bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.1bn | 2018-04-01 → 2019-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥20.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥24.5bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥17.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥21.0bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥9.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥606m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥17.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥18.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥19.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥19.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥132m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥10.5bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥137m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥457.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥467.3bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥432.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥408.9bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥250.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥360.6bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥370.5bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥96.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥96.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥50.6bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥40.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥50.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥22.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥50.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥154.96 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.62 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.17 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-92.71 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.21 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥153.15 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥161.08 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥72 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥38 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥759.31 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥763.79 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥428.12 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥355.31 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥445.36 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 20.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.3% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 11.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 9.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.0% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 20.4% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 27.6% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 125,522,074 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 124,144,242 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 114,831,084 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,973,941 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 111,871,099 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 151 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 175 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 181 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 186 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 175 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 512 pure |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥15.5bn |
| Diabetes Managementreportable segment | employees | at 2023-03-31 | 2639 pure |
| Diabetes Managementreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥111.8bn |
| Diabetes Managementreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥111.8bn |
| Diabetes Managementreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥26.7bn |
| Diagnostics And Life Sciencesreportable segment | employees | at 2023-03-31 | 2388 pure |
| Diagnostics And Life Sciencesreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥108.8bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥108.8bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥1.1bn |
| Healthcare Solutionsreportable segment | employees | at 2023-03-31 | 3864 pure |
| Healthcare Solutionsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥133.6bn |
| Healthcare Solutionsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥133.6bn |
| Healthcare Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥9.8bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥354.2bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥354.2bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥35.5bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2022-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥18.0bn |
| Diabetes Managementreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥109.4bn |
| Diabetes Managementreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥109.4bn |
| Diabetes Managementreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.3bn |
| Diagnostics And Life Sciencesreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥92.2bn |
| Diagnostics And Life Sciencesreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥92.2bn |
| Diagnostics And Life Sciencesreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥14.1bn |
| Healthcare Solutionsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥136.3bn |
| Healthcare Solutionsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥136.3bn |
| Healthcare Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥17.0bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥337.9bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥337.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥26.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 151 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,100
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 16 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 151 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 16 | |
| Research and development expenses research and development activities | CurrentYearDuration | 9931000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 2547000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 1773000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 4458000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 11516000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36976-000DiabetesManagementReportableSegmentMember | 1071000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36976-000HealthcareSolutionsReportableSegmentMember | 7755000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember | 2547000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 125522074 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 125777068 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 125522074 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 125777068 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 15 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 34 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 373 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 120 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 68 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 18844 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 19454 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 54604 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 6689 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 463914 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 606164 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 647 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 123033 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 1255051 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 16974 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0435 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0053 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.3696 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.4830 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0005 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.0980 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 47994000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.3830 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 21870000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1745 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 12297000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0981 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 11266000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0899 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 5714000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0456 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |